Zoetis, Inc. (NYSE:ZTS) reported adjusted earnings for the third quarter of 2026 at $1.75 per share, surpassing the Zacks Consensus Estimate of $1.51. This marks an improvement over the previous year’s third-quarter earnings of $1.70 per share.
The company experienced a slight decline in total revenues by 1% year-over-year, reaching $2.4 billion. Nevertheless, this figure slightly exceeded the Zacks Consensus Estimate of $2.3 billion. Following these results, Zoetis’ stock price increased by 7.5%.
Despite the recent positive performance, Zoetis shares have dropped 27.5% year-to-date, contrasting with a 3.4% decline in the broader industry.
Detailed Analysis of Zoetis’ Q3 Performance
Zoetis generates most of its revenue from a diverse range of medicines and vaccines designed for livestock and companion animals. The company operates through two main geographical segments: the United States and International.
In the U.S. segment, revenues fell by 6% year-over-year to $1.25 billion, although this was still above the Zacks Consensus Estimate of $1.17 billion. Sales of companion animal products in the U.S. decreased by 8% to $980 million, influenced by price sensitivity due to macroeconomic factors, increased competition in dermatology, and generic alternatives.
Despite competitive pressures, Zoetis’ dermatology segment managed to mitigate market share losses through promotional activities. The Simparica Trio product maintained its leading market position with a 23% clinic patient share, even as veterinary visits for flea, tick, and heartworm treatments declined.
Conversely, sales of livestock products in the U.S. rose by 5% to $266 million, driven by strong performance in cattle, swine, and poultry segments, aided by the recovery of Ceftiofur supply and robust vaccine demand. However, the destocking of Dectomax partially offset these gains.
Internationally, Zoetis’ revenues increased by 4% year-over-year to $1.12 billion, slightly surpassing the Zacks Consensus Estimate of $1.11 billion. Sales of companion animal products outside the U.S. grew by 1% on a reported basis to $585 million, remaining flat on an organic operational basis. This growth was mainly due to the parasiticides and osteoarthritis pain portfolios, although it was partially offset by a decline in key dermatology product sales.
Livestock product sales outside the U.S. experienced an 8% increase on a reported basis and a 9% increase on an organic operational basis, reaching $531 million. This growth was primarily driven by strong results in cattle and fish products.
2026 Financial Guidance
Zoetis has adjusted its revenue guidance for 2026, raising the lower end of its forecast range while maintaining the upper end. The company now anticipates revenues between $9.22 billion and $9.32 billion, reflecting an expected organic operational growth of negative 2% to 1%, compared to the previous range of $9.12 billion to $9.32 billion.
For adjusted earnings, Zoetis projects a range of $6.25 to $6.35 per share for 2026, an increase from the prior expectation of $6.15 to $6.25 per share. The company also revised its expectations for adjusted research and development expenses to between $705 million and $715 million, down from the previous estimate of $720 million to $730 million.
Comparative Analysis with Other Biotech Stocks
Zoetis currently holds a Zacks Rank #4 (Sell). In comparison, TG Therapeutics (NASDAQ:TGTX) has a Zacks Rank #1 (Strong Buy), while ImmunityBio (NASDAQ:IBRX) and Amneal Pharmaceuticals (NYSE:AMRX) both carry a Zacks Rank #2 (Buy).
Over the past month, earnings per share estimates for TG Therapeutics have increased from 92 cents to 94 cents for 2026, with 2027 estimates rising from $2.65 to $2.66. TGTX shares have surged 106.8% year-to-date. Despite missing estimates in three of the last four quarters, TG Therapeutics had an average surprise of 184.65%.
ImmunityBio’s loss per share estimates for 2026 remain at 97 cents, while 2027 estimates have improved from 14 cents to 11 cents. IBRX shares have soared 351% year-to-date, with earnings beating estimates in three of the last four quarters, averaging a 13.40% surprise.
Amneal Pharmaceuticals’ earnings estimates for 2026 have risen from $1.03 to $1.04 per share, and 2027 estimates have increased from $1.16 to $1.19. AMRX shares have climbed 58.4% year-to-date, with earnings exceeding estimates in all four of the last quarters, averaging a 27.21% surprise.
Footnotes:
- Zoetis’ Q3 earnings per share exceeded expectations by $0.24. Source.
- Zoetis’ revenue for the third quarter was $2.4 billion, slightly above estimates. Source.
- Zoetis’ stock increased by 7.5% following the earnings report. Source.
Featured Image: Megapixl @ 123dartist
